两种新的凋亡诱发蛋白的聚合作用及其对细胞凋亡的调控

Asy (apoptosis /saibousi Yutsudo)是日本Yutsudo小组于1999年发现的一个新的人类细胞凋亡诱发基因. 2000年齐兵等人通过酵母双杂交系统从人肺细胞系(W1-38) cDNA 文库中克隆出一个能与ASY蛋白相互作用的蛋白的新基因hap (homologue of asy protein). 已经证明ASY能在酵母细胞和哺乳动物细胞中形成同源二聚体, ASY与HAP能在酵母细胞中形成异源二聚体, ASY和HAP均能诱发肿瘤细胞Saos2和CGL4凋亡. 通过酵母双杂交系统证明HAP能在酵母细胞中形成同源二聚体; 通过交叉免疫沉淀证明HAP与ASY能在人类细胞中形成异源二聚体. 通过AnnexinV, TUNEL, DNA Ladder和流式细胞计数等检测凋亡的技术, 对asy, hap单独转染或共转染的人类正常细胞或肿瘤细胞的凋亡进行定性或定量检测, 证明ASY和HAP不仅诱发人类肿瘤细胞凋亡, 而且能诱发人类正常细胞凋亡, 并且证明由ASY与HAP形成的异源二聚体可降低由ASY和HAP各自形成的同源二聚体诱发细胞凋亡的活性, 揭示ASY与HAP形成同源或异源二聚体是调控人类细胞凋亡的重要机制.     

HAP蛋白疏水区的聚合功能及其与细胞凋亡的关系

asy和hap是一对新的细胞凋亡诱发基因 .二者单独转染细胞均能诱发细胞凋亡 ,能在酵母和哺乳动物细胞中形成同源二聚体 ,二者共转染酵母和哺乳动物细胞能形成异源二聚体 .同源二聚体诱发细胞凋亡 ,异源二聚体降低同源二聚体诱发细胞凋亡的活性 .氨基酸序列表明 ,HAP(homologousofASYprotein)含有内质网挽回模体 (KKKAE)、第一疏水区和第二疏水区 .对 3个功能区的缺失突变体研究显示 ,缺失内质网定位信号的HAPΔERS蛋白保留着同源聚合和与ASY异源聚合的能力 ,而分别缺失第一、第二疏水区的突变体HAPΔ4 8 139、HAPΔ15 7 2 18则丧失以上功能 ;通过流式计数法计算 3个缺失突变体诱发细胞凋亡比率 ,用生物统计学方法说明不同的比率与HAP诱发细胞凋亡的比率相比都有显著差异 .说明内质网定位信号、疏水区在HAP蛋白的诱发细胞凋亡过程中起重要作用 ,进一步揭示了HAP诱发细胞凋亡的机制 .     

病毒基因与细胞凋亡

细胞凋亡是受遗传控制的细胞自灭过程,是机体维持稳态的主要机制之一。是一种典形的细胞程序化死亡,细胞程序化死亡的诱导与调控机制是当今生物学中非常活跃的研究领域,涉及到细胞生物学、病毒学、免疫学,发育生物学,致癌生物学等学科,具有重要的理论与实践意义。引起细胞凋亡的因素很多,本文仅就病毒基因与细胞凋亡的关系,主要以疱疹病毒科,腺病毒科,杆状病毒科和逆转录病毒中某些病毒与细胞凋亡相关的基因及其结构,作用     

动物细胞凋亡相关基因在植物中的同源性研究进展

细胞凋亡是由基因调节的主动过程.对动物细胞凋亡相关基因在植物中的同源性的研究发现,dad-1基因的结构和功能在动物和植物中均具有保守性.动物中的其他细胞凋亡相关基因,如ras、myc、Rb、p53、bcl-2 等基因,在植物中均有其同源序列,有的在植物中找到了功能相似的基因.细胞凋亡的调控机制在生物进化过程中,不但具有一定程度的保守性,而且在调控机制上具有多样性.     

核孤儿受体TR3/nur77与一种新细胞凋亡机制

核孤儿受体TR3/nur77是一种立刻早期基因（immediate-early gene）的产物,与固醇类激素受体结构相似,是核受体超家族的重要成员之一,可被多种生长因子或凋亡诱导剂诱导表达,具有复杂的生物学功能,涉及细胞增殖、分化发育和凋亡过程.最近对其诱导凋亡机制的研究取得了重大进展,发现当细胞受到凋亡诱导剂刺激后,TR3基因表达升高,其产物从细胞核移位至线粒体膜,引起细胞色素c释放,从而导致细胞凋亡.即TR3的转录激活功能和诱导凋亡功能是由其不同的亚细胞定位结合所决定的,其诱导凋亡过程与其对基因的反式激活功能无关.核转录因子p53也具有类似情况.这种核转录因子由细胞核移位至细胞浆并发挥生物学功能的调控方式是一种新模式,可能具有重要的生物学意义.     

病毒基因与细胞凋亡

细胞凋亡（Ａｐｏｐｔｏｓｉｓ）是受遗传控制的细胞自灭过程,是机体维持稳态的主要机制之一。是一种典形的细胞程序化死亡（ｐｒｏｇｒａｍｍｅｄｃｅｌｌｄｅａｔｈ）,细胞程序化死亡的诱导与调控机制是当今生物学中非常活跃的研究领域,涉及到细胞生物学,病毒学、免疫学、发育生物学、致癌生物学等学科。具有重要的理论与实践意义。引起细胞凋亡的因素很多,本文仅就病毒基因与细胞凋亡的关系,主要以疤疹病毒科,腺病毒科,杆状病毒科和逆转录病毒中某些病毒与细胞凋亡相关的基因及其结构,作用方式和分子机理的研究结果进行综述并对以后研究方向作些展望。     

EB病毒潜伏膜蛋白1调控细胞凋亡的cDNA阵列分析

为探讨EB病毒潜伏膜蛋白（LMP1）介导细胞凋亡和抑制细胞凋亡双重效应的机制,采用已建立的受四环素调控的LMP1表达的鼻咽癌系统（pTet-on-LMP1 HNE2),定量诱导pTet-on-LMP1 HNE2细胞LMP1动态表达,分别与含有细胞凋亡相关基因为主的Atlas apoptosis cDNA expression array膜杂交,分析LMP1介导 的表达差异基因。结果表明：①LMP1介导细胞凋亡和抑制细胞凋亡的基因的表达,同时上调或下调某些细胞凋亡相关基因的表达;②LMP1不仅介导细胞凋亡和抑制凋亡基因的表达,同时介导细胞分裂分化和增殖基因的表达,LMP1同时介导功能不同甚至功能相反的基因表达;③LMP1介导的基因表达与其表达持续时间和表达水平相关,不同表达水平和不同表达时间介导的基因表达谱不同。因此,LMP1具有介导细胞凋亡和抑制凋亡基因表达的双重生物学效应,同时介导细胞增殖、细胞周期、细胞凋亡等多种生物学效应基因的表达,从而参与细胞的癌变。     

重组β酪蛋白磷酸肽二聚体基因的构建、表达及其生物活性分析

生物活性短肽 β酪蛋白磷酸肽 (β CPP)能够增加细胞对二价离子的吸收、促进受精过程并对细胞增殖产生影响 .为深入研究其生物学功能 ,采用基因工程方法得到β CPP的二聚体基因并构建真核表达载体 ,转染CHO细胞建立稳定表达细胞系 .鉴定纯化所表达产物 ,考察表达产物对精子细胞内游离Ca2 + 水平、细胞增殖和细胞凋亡等方面的影响 .结果表明 ,重组 β CPP二聚体能够显著增加精子细胞对Ca2 + 的吸收、促进脾细胞的增殖并诱导某些肿瘤细胞的凋亡 ,有着广泛的生物学活性和潜在的药理学意义     

线粒体与细胞凋亡调控

细胞凋亡是一个受到一系列相关基因严格调控的细胞死亡过程。线粒体是细胞凋亡调控的活动中心。在凋亡因子的刺激下,线粒体释放出不同促凋亡因子如细胞色素C、Smac／Diablo等,激活细胞内凋亡蛋白酶Caspase。我们发现,活化后的Caspase可以反过来作用于线粒体,引发更大量线粒体细胞色素c的释放,构成细胞色素c释放的正反馈调节机制,从而导致电子传递链的中断、膜电势的丧失、胞内ROS的升高以及线粒体产生ATP功能的完全丧失。Bcl-2家族蛋白在细胞色素C释放和细胞凋亡调控中起关键作用。     

细胞凋亡的结构生物学研究进展

在多细胞生物体内,细胞会发生编程性死亡(即细胞凋亡),使得细胞数量得到精确调控。细胞凋亡调控的异常与癌症、自身免疫病、神经退行性疾病等疾病密切相关。在过去的二十年里,人们详细地研究了参与细胞凋亡调控的分子机制。该文综述了近年来利用结构生物学手段,对参与细胞凋亡调控的分子,主要是Caspase和与Caspase活性调控直接相关的蛋白功能的研究进展。     

BAX and BAK1 are dispensable for ABT-737-induced dissociation of the BCL2-BECN1 complex and autophagy

Disruption of the complex of BECN1 with BCL2 or BCL2L1/BCL-X_L is an essential switch that turns on cellular autophagy in response to environmental stress or treatment with BH3 peptidomimetics. Recently, it has been proposed that BCL2 and BCL2L1/BCL-X_L may inhibit autophagy indirectly through a mechanism dependent on the proapoptotic BCL2 family members, BAX and BAK1. Here we report that the BH3 mimetic, ABT-737, induces autophagy in parallel with disruption of BCL2-BECN1 binding in 2 different apoptosis-deficient cell types lacking BAX and BAK1, namely in mouse embryonic fibroblasts cells and in human colon cancer HCT116 cells. We conclude that the BH3 mimetic ABT-737 induces autophagy through a BAX and BAK1-independent mechanism that likely involves disruption of BECN1 binding to antiapoptotic BCL2 family members.     

BCL2 and related prosurvival proteins require BAK1 and BAX to affect autophagy

It is widely thought that prosurvival BCL2 family members not only inhibit apoptosis, but also block autophagy by directly binding to BECN1/Beclin 1. To distinguish whether BCL2, BCL2L1/BCL-XL, or MCL1 influence autophagy directly, or indirectly, through their effects on apoptosis, we compared normal cells to those lacking BAX and BAK1. In cells able to undergo mitochondria-mediated apoptosis, inhibiting the endogenous prosurvival BCL2 family members induces both autophagy and cell death, but when BAX and BAK1 are deleted, neither inhibiting nor overexpressing BCL2, BCL2L1, or MCL1 causes any detectable effect on LC3B lipidation, LC3B turnover, or autolysosome formation. These results show that prosurvival BCL2 family members influence autophagy only indirectly, by inhibiting activation of BAX and BAK1.     

BCL2 and related prosurvival proteins require BAK1 and BAX to affect autophagy

It is widely thought that prosurvival BCL2 family members not only inhibit apoptosis, but also block autophagy by directly binding to BECN1/Beclin 1. To distinguish whether BCL2, BCL2L1/BCL-XL, or MCL1 influence autophagy directly, or indirectly, through their effects on apoptosis, we compared normal cells to those lacking BAX and BAK1. In cells able to undergo mitochondria-mediated apoptosis, inhibiting the endogenous prosurvival BCL2 family members induces both autophagy and cell death, but when BAX and BAK1 are deleted, neither inhibiting nor overexpressing BCL2, BCL2L1, or MCL1 causes any detectable effect on LC3B lipidation, LC3B turnover, or autolysosome formation. These results show that prosurvival BCL2 family members influence autophagy only indirectly, by inhibiting activation of BAX and BAK1.     

Glucocorticoids uncover a critical role for ASH2L on BCL-X expression regulation in leukemia cells

Targeting the apoptosis machinery is a promising therapeutic approach in myeloid malignancies. BCL2L1 is a well-known glucocorticoid-responsive gene and a key apoptosis regulator that, when over-expressed, can contribute to tumor development, progression and therapeutic resistance. Moreover, synthetic glucocorticoids, like dexamethasone, are frequently used in the treatment of hematopoietic diseases due to its pro-apoptotic properties. We report here that the trithorax protein ASH2L, considered one of the core subunits of H3K4-specific MLL/SET methyltransferase complexes, contributes to anti-apoptotic BCL-X_L over-expression and cell survival in patient-derived myeloid leukemia cells. We find that the unliganded glucocorticoid receptor (uGR) and ASH2L interact in a common protein complex through a chromatin looping determined by uGR and ASH2L binding to BCL2L1 specific +58 HRE and promoter region, respectively. Upon addition of dexamethasone, GR and ASH2L recruitment is reduced, BCL-X_L expression diminishes and apoptosis is induced consequently. Overall, our findings indicate that uGR and ASH2L may act as key regulatory players of BCL- X_L upregulation in AML cells.     

BCL2A1: the underdog in the BCL2 family

B-cell lymphoma 2 (BCL2) proteins are important cell death regulators, whose main function is to control the release of cytochrome c from mitochondria in the intrinsic apoptotic pathway. They comprise both pro- and anti-apoptotic proteins, which interact in various ways to induce or prevent pore formation in the outer mitochondrial membrane. Due to their central function in the apoptotic machinery, BCL2 proteins are often deregulated in cancer. To this end, many anti-apoptotic BCL2 proteins have been identified as important cellular oncogenes and attractive targets for anti-cancer therapy. In this review, the existing knowledge on B-cell lymphoma 2-related protein A1 (BCL2A1)/Bcl-2-related gene expressed in fetal liver (Bfl-1), one of the less extensively studied anti-apoptotic BCL2 proteins, is summarized. BCL2A1 is a highly regulated nuclear factor κB (NF-κB) target gene that exerts important pro-survival functions. In a physiological context, BCL2A1 is mainly expressed in the hematopoietic system, where it facilitates survival of selected leukocytes subsets and inflammation. However, BCL2A1 is overexpressed in a variety of cancer cells, including hematological malignancies and solid tumors, and may contribute to tumor progression. Therefore, the development of small molecule inhibitors of BCL2A1 may be a promising approach mainly to sensitize tumor cells for apoptosis and thus improve the efficiency of anti-cancer therapy.     

Apoptosis Induced by Differentiation or Serum Deprivation in an Immortalized Central Nervous System Neuronal Cell Line

Abstract: To characterize the nature of programmed cell death (PCD) induced in neuronal cells during development, three regulators of apoptosis were investigated: one, the bcl-2-related genes, modulate cell survival, and the other two, the interleukin-1β converting enzyme (ICE)-related enzymes and the tumor suppressor protein p53, have been implicated as mediators of apoptosis. These regulators were studied in H19-7 cells, an SV40 T^ts-immortalized rat hippocampal neuronal cell line that can be differentiated with basic fibroblast growth factor at the nonpermissive temperature, resulting in a rapid attrition of cells by apoptosis. PCD occurred by two mechanisms in H19-7 cells: The first was initiated by removal of serum from undifferentiated cells, and the second was a consequence of neuronal differentiation. In differentiated H19-7 cells, the survival time was increased by both human bcl-2 and bcl-x_L, and this could be reversed by bcl-x_S.Addition of a peptide inhibitor of the ICE enzyme family to H19-7 cells resulted in a transient protection against differentiation-associated apoptosis, whereas no further protection was observed in the BCL-2- or BCL-X_L-expressing cells. Shifting the differentiated cells to 33°C to inactivate p53 did not significantly affect the apoptotic process, indicating that apoptosis induced by neuronal differentiation is not dependent on the continued presence of p53. By contrast, in undifferentiated cells, cell loss induced by transfer to serum-free media occurred more rapidly on inactivation of large T, consistent with p53 involvement. This medium-induced decrease in cell survival could not be rescued by the ICE inhibitor but was partially rescued by BCL-2 or BCL-X_L. Furthermore, studies involving expression of BCL-2 and BCL-X_L alone or together revealed differences in the survival dependent on the cellular environment. These results suggest that apoptosis of neuronal cellsoccurs by at least two processes: one in undifferentiated cells initiated by removal of serum and one linked to differentiation. The data implicate the ICE enzyme family but not p53 in apoptosis induced by differentiation and demonstrate that either BCL-2 or BCL-X_L can prolong the survival of differentiated neuronal cells.     

MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer

Lung cancer is the most frequent cause of cancer-related death in this country for men and women. MicroRNAs (miRNAs) are a family of small non-coding RNAs (approximately 21-25 nt long) capable of targeting genes for either degradation of mRNA or inhibition of translation. We identified aberrant expression of 41 miRNAs in lung tumor versus uninvolved tissue. MiR-133B had the lowest expression of miRNA in lung tumor tissue (28-fold reduction) compared to adjacent uninvolved tissue. We identified two members of the BCL-2 family of pro-survival molecules (MCL-1 and BCL2L2 (BCLw)) as predicted targets of miR-133B. Selective over-expression of miR-133B in adenocarcinoma (H2009) cell lines resulted in reduced expression of both MCL-1 and BCL2L2. We then confirmed that miR-133B directly targets the 3′UTRs of both MCL-1 and BCL2L2. Lastly, over-expression of miR-133B induced apoptosis following gemcitabine exposure in these tumor cells. To our knowledge, this represents the first observation of decreased expression of miR-133B in lung cancer and that it functionally targets members of the BCL-2 family.     

Repression of the BH3-only molecule PMAIP1/Noxa impairs glucocorticoid sensitivity of acute lymphoblastic leukemia cells

Glucocorticoid (GC)-induced apoptosis plays a major role in the treatment of acute lymphoblastic leukemia (ALL) and related malignancies. Members of the BCL2 family of pro- and anti-apoptotic proteins are regulated by GC, but to what extent these regulations contribute to GC-induced cell death and resistance development is poorly understood. Using primary lymphoblasts from ALL children during systemic GC monotherapy and related cell lines, we have previously shown that the response of the BCL2 rheostat to GC was dominated by induction of the pro-apoptotic BH3-only molecules BMF and BCL2L11/Bim, but we also observed an unexpected significant repression of the pro-apoptotic BCL2 protein PMAIP1/Noxa. Here, we report that GC represses Noxa mRNA levels and also interferes with its protein stability in a proteasome-dependent manner. Prevention of GC-mediated Noxa repression by conditional expression of transgenic Noxa changed the kinetics of GC-induced apoptosis to resemble cell death induced by BimEL alone. Hence, GC appear to activate functionally relevant pro- as well as anti-apoptotic pathways in ALL cells. Interfering with the anti-apoptotic component of the GC response might contribute to improved therapeutic approaches and circumvention of resistance to this therapy.     

Exploring the anti-apoptotic role of HAX-1 versus BCL-XL in cytokine-dependent bone marrow-derived cells from mice

HS-1-associated protein X-1 (HAX-1) is a multi-functional protein that has been implicated in the regulation of apoptosis, cell motility and calcium homeostasis. In the present study, we set out to assess the postulated functional resemblance of HAX-1 to the BCL-2 family of anti-apoptotic proteins using non-transformed, cytokine-dependent murine bone marrow cells as a model system. BCL-X_L, but not HAX-1 protected against cytokine withdrawal-induced apoptosis while HAX-1 and BCL-X_L significantly reduced thapsigargin-triggered (calcium-dependent) apoptosis. The data argue in favor of cell type- and stimulus-specific roles of HAX-1 in regulation of cell survival.     

Piperlongumine restores the balance of autophagy and apoptosis by increasing BCL2 phosphorylation in rotenone-induced Parkinson disease models

Parkinson disease (PD) is the second most common neurodegenerative disorder after Alzheimer disease and is caused by genetics, environmental factors and aging, with few treatments currently available. Apoptosis and macroautophagy/autophagy play critical roles in PD pathogenesis; as such, modulating their balance is a potential treatment strategy. BCL2 (B cell leukemia/lymphoma 2) is a key molecule regulating this balance. Piperlongumine (PLG) is an alkaloid extracted from Piper longum L. that has antiinflammatory and anticancer effects. The present study investigated the protective effects of PLG in rotenone-induced PD cell and mouse models. We found that PLG administration (2 and 4 mg/kg) for 4 wk attenuated motor deficits in mice and prevented the loss of dopaminergic neurons in the substantia nigra induced by oral administration of rotenone (10 mg/kg) for 6 wk. PLG improved cell viability and enhanced mitochondrial function in primary neurons and SK-N-SH cells. These protective effects were exerted via inhibition of apoptosis and induction of autophagy through enhancement of BCL2 phosphorylation at Ser70. These results demonstrate that PLG exerts therapeutic effects in a rotenone-induced PD models by restoring the balance between apoptosis and autophagy.

Abbreviations: 6-OHDA, 6-hydroxydopamine; ACTB, actin, beta; BafA1, bafilomycin A₁; BAK1, BCL2-antagonist/killer 1; BAX, BCL2-associated X protein; BCL2, B cell leukemia/lymphoma2; BECN1, Beclin 1, autophagy related; CoQ10, coenzyme Q₁₀; COX4I1/COX IV, cytochrome c oxidase subunit 4I1; CsA, cyclosporine A; ED50, 50% effective dose; FITC, fluorescein isothiocyanate; GFP, green fluorescent protein; HPLC, high-performance liquid chromatography; JC-1, tetraethylbenz-imidazolylcarbocyanine iodide; LC3, microtubule-associated protein 1 light chain3; LC-MS/MS, liquid chromatography-tandem mass spectrometry; LDH, lactate dehydrogenase; l-dopa, 3, 4-dihydroxyphenyl-l-alanine; MAPK8/JNK1, mitogen-activated protein kinase 8; MMP, mitochondrial membrane potential; mPTP, mitochondrial permeability transition pore; mRFP, monomeric red fluorescent protein; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; NFE2L2/NRF2, nuclear factor, erythroid derived 2, like 2; PD, Parkinson disease; PLG, piperlongumine; pNA, p-nitroanilide; PI, propidium iodide; PtdIns3K, phosphatidylinositol 3-kinase; PtdIns3P, phosphatidylinositol-3-phosphate; PTX, paclitaxel; Rap, rapamycin; SQSTM1/p62, sequestosome 1; TH, tyrosine hydroxylase; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling; WIPI2, WD repeat domain, phosphoinositide interacting 2; ZFYVE1/DFCP1, zinc finger, FYVE domain containing 1.